Nicox

Nicox S.A. leads eye‑care biotech with Vyzulta® and NO‑donor drugs, partnering top pharma to expand glaucoma and allergy treatments, driving future growth.

Nicox completes all data for NCX 470, a glaucoma therapy, ahead of 2026 U.S. and China NDA filings, positioning its eye‑care pipeline for regulatory approval.

Discover how Nicox S.A. is reshaping eye care with cutting‑edge glaucoma, allergy, and inflammation therapies, backed by global partnerships and a robust pipeline.

Nicox S.A. continues to advance its ophthalmic therapies through innovative treatments and strategic partnerships, despite market fluctuations.

Nicox S.A. is a French biotechnology company focused on researching and developing innovative ophthalmic therapies for various eye diseases, with a diverse product pipeline and collaborations with major pharmaceutical companies.